Sanofi (SNY)
| Market Cap | 112.73B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | 1.22B |
| EPS (ttm) | 8.67 |
| PE Ratio | 10.54 |
| Forward PE | 9.61 |
| Dividend | $1.60 (3.39%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 2,211,642 |
| Open | 46.27 |
| Previous Close | 46.50 |
| Day's Range | 46.10 - 47.25 |
| 52-Week Range | 44.62 - 60.12 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 61.50 (+30.3%) |
| Earnings Date | Jan 29, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 30.30% from the latest price.
News
Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema
Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 wi...
Sanofi CEO Paul Hudson: AI will change the cost and speed of drug development
Sanofi CEO Paul Hudson discusses the impact of AI in the pharmaceutical space during an interview with CNBC at the World Economic Forum in Davos on Thursday.
Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss state of the pharmaceutical landscape, future of drug pricing, drug pipeline, impact of AI, and more.
Press Release: Myqorzo and Redemplo approved in China
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi's long-term commitment to C...
Sanofi sees softness in U.S. vaccine demand in near term
Sanofi chief executive Paul Hudson said on Wednesday the U.S. is likely to see a slight weakness in vaccine demand this year due to misinformation and heightened scrutiny under the current administrat...
Sanofi: Information concerning the total number of voting rights and shares - December 2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa...
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced toda...
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Sanofi to acquire US biotech Dynavax for $2.2 billion
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agr...
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP...
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce...
Sanofi: Information concerning the total number of voting rights and shares - November 2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
